Petvivo Holdings Inc

Good afternoon, everyone. Thank you for joining us today to discuss our results for our fiscal year 2026, ended March 31st, 2026. Before we begin, I'd like to direct your attention to the forward-looking statements slide displayed on your screen. Throughout today's call, we may discuss the company's future plans, expectations, objectives, anticipated results, and other forward-looking statements. Please take a moment to review the information on this slide. I will also provide the company's complete safe harbor statement at the conclusion of today's call. Hosting the call today is our Chief Executive Officer, John Lai. and our Chief Financial Officer, Garry Lowenthal, as well as myself, John Dolan, Pet Vivo's Chief Business Development Officer and General Counsel. Following our remarks, we'll open the call to your questions. Then before we conclude today's call, I will provide some important cautions regarding the forward-looking statements made during the call. Before we begin, I'd like to remind everyone that the call is being recorded in order to make it available for replay later today. www.petvivo.com The many exciting new opportunities we have been pursuing over the past year have required extraordinary attention in capital deployment to ensure their effective deployment and market acceptance. We remain razor focused on our primary objective, which is the pursuit of creating strong, high-margin, reoccurring revenue streams with this to support the highest valuation of our company for the benefit of our stakeholders. The strong clinical validation and increasing market adoption of our flagship product, Spring, with Osseocushion technology has brought us far along in our journey. Over the course of the past year, it has set the stage for the launch of new technologies and products for both animal and human. That promise to exceed even Spring's original great potential. The year was highlighted by tremendous progress with new strategic alliances and collaborations with new key partners. This includes Digitalandia, an industry-leading pioneer in agentic AI solutions, with whom we have an exclusive 10-year white-label licensing agreement for their breakthrough next-generation agentic pet technology. This unique and innovative technology features specialized diagnostic AI agents, that are protected by proprietary IP and five patent pending innovations. Among this technology's multiple capabilities, it addresses many of the critical challenges facing today's veterinarian practices and the industry at large. This includes especially skyrocketing client acquisition costs and the challenges in capturing the fast-growing demographic of the Gen Z pet parents. Based on this new partnership, we publicly launched a beta program of our new Petvivo.ai veterinary practice platform that is exclusively powered by the agentic pet technology. Petvivo.ai is a new AI-powered software as a service platform for veterinarians that we believe is the first of its kind on the market. As such, we believe it provides as a strong first mover advantage with unique benefits and capabilities it provides veterinarian clinics. It employs automated AI-powered engagement that intelligently converts the potential customer leads it generates into paying veterinary customers. An initial select group of veterinarian practices, which we have engaged under a beta program, have been providing us tremendous positive feedback and impressive results. PetVivo AI is has demonstrated a remarkable 50% to 90% reduction in veterinary customer acquisition costs, lowering it from the $80 to $400 that is typically spent on each new customer target down to less than $43. This AI-powered solution complements our medical device offerings, which we market to a network of thousands of veterinary clinics across North America and Europe. We see it creating new inroads for the adoption of our spring medical device and other therapeutic offerings. Perhaps most importantly, Pepvivo AI also creates a new reoccurring revenue stream with very high 80% to 90% gross margins along with low capex scalability. The final training of its AI engine is currently underway using real-world scenarios in our beta users with the official commercial launch expected within the next few months. Veterinarians can request a free demo of this solution on our newly launched Pet Vivo AI website and experience firsthand how the power of this technology can transform their practice. In support of the launch of Pet Vivo AI, earlier this year, Digitallandia published a comprehensive technical white paper documenting the agentic pet AI framework that underpins this technology. The paper validates the technical foundation underlying this new B2B platform, and it provides veterinary professionals, investors, and industry stakeholders with a detailed view into the multi-agent artificial intelligence architecture that enables its transformative clinical and economic benefits. Based on the conclusions of this report, we expect our pet vivo AI solution to rival the adoption of other mainstream AI applications, and as I mentioned, We also expect it to create new visibility for our brands, particularly spring with Osseocushion technology and several new solutions in our product pipeline. For our part, we launched an online video explainer that can walk you through the two-part ecosystem of PetVivo AI. It shows how PetVivo AI intelligently connects pet parents with veterinary practices looking for new clients. If you haven't yet watched it, We very much encourage you to do so, as it will help you understand why we are so excited about this new offering. Regarding other key partners, we continue to advance our partnership with Austin, Texas-based Veterinary Growth Partners. BGP is a management services organization which helps veterinary practices improve their efficiency and profitability with management and marketing tools, consulting, and the introduction of new vendor relationships. BGP is committed to actively promoting our spring with osseocushion technology to its expansive member network of more than 7,300 veterinary clinic members across the U.S. We've been focused on product training of the veterinarians in their network and we're planning to introduce our new Pet Vivo AI practice management platform to their clinic membership following this training period for spring. During the last quarter of our fiscal year, we completed the majority of the tasks of Stage B of our three-part R&D program with Piezo Biomembrane. At the spin-off from the University of Connecticut, PMB has been advancing its patented biodegradable piezoelectric materials for implantable and regenerative applications. The revolutionary Functional biomaterials are designed to promote regeneration, restoration, and or remodeling of damaged or injured tissue and bone in animals and humans. Stage A determined that a respective product could be combined into a single offering and particularly one that demonstrates enhanced piezoelectric activity with this activity potentially providing therapeutic benefits to animals and humans. Stage B determined that combined offering could be produced at scale, and it provided preliminary indications of safety for administration in animals. Soon with the commencement of Stage C, we will definitively determine safety and efficacy. We plan to also pursue FDA clearance for a number of products incorporating the piezoelectric materials in our biomaterial found in spring, which mimics the extracellular matrix of animals and humans. Of course, the study and product development process will proceed more quickly given last week's announcement of the acquisition of Paeso Biomembrane. As a newly wholly owned subsidiary of Pet Vivo, PDM will continue to focus on the development, commercialization, licensing, and management of next-generation biomaterials, regenerative and restorative therapeutic technologies, and related intellectual property. PBM brings to us an advanced technology platform with a multitude of valuable assets, including proprietary know-how, licensed intellectual property rights, patents and patent applications, trade secrets, as well as biomaterials, formulations, regulatory assets, manufacturing information, development materials, and clinical information. All of this supports our development of functional biomaterials, medical devices, and other beneficial therapeutic applications for animal and human health. The PBM acquisition represents a transformative step in our long-term growth strategy that includes the development of multiple medical device and therapeutic products for both animal and human applications. By combining PBMs scientific innovations with our existing product development capabilities, commercialization expertise, regulatory expertise, and public company infrastructure, we expect our combination to accelerate the advancement of technologies that will serve as the foundation for numerous future products and strategic opportunities. The combined platform also creates new opportunities for securing government and private development grants and research collaborations, as well as R&D tax credit programs, with the pursuit of many such opportunities already underway. I should note that the completion of the acquisition is subject to customary closing conditions, including completion of due diligence, satisfaction of specified closing obligations, and completion of certain financing activities currently underway and advancing smoothly. Now, before we get into more of the other exciting recent developments and our outlook for the rest of the year, I would like to turn the call over to our Chief Financial Officer, Garry Lowenthal, who will take us through the financial details for the quarter and year. Garry?

Thank you, John, and good afternoon, everyone. Thank you for joining us today to discuss the results of our fiscal year ended March 31, 2026. Revenues for the year increased 1% to $1.14 million. Revenues for the period consisted of sales of spring and precise PRP products, with sales to our distributor network totaling $886,000 and direct sales to veterinary clinics totaling $255,000. This compares to the previous year, where sales consisted entirely of spring, with distributor sales totaling $956,000 and veterinary clinic sales at $176,000. We should note that in the third quarter of fiscal 2025, we had a special promotion with our distributors and vet clinic for a spring product, which was not repeated in the third quarter of fiscal 2026. We believe this led to proportionally lower sales of spring during the year. We also believe the lower spring sales were also due to customers opting to use precise PRP alone and not in conjunction with spring, Our renewed efforts to better educate our customers on the benefits of spring, combined with the expansion of our sales force with better sales abilities over recent months, has restored greater sales in spring. We expect this improvement to continue over future quarters. Gross profit for fiscal year ending 2026 totals $754,700.00 or 66.1% of revenues. It decreased from 994,900 or 87.8% of revenues in the previous year. The decrease was due to the low gross margin associated with sales of our precise PRP product line per our license agreement with VETSTEM. However, we were able to maintain fairly good overall high gross margin despite the lower margin associated with precise PRP and the greater proportion of this lower margin product in our sales mix. In addition to lower than expected market acceptance for the precise PRP products, the low growth margins associated with the PRP product is one of the primary reasons we decided to renegotiate our VETSTEM partnership and evaluate the long-term viability of selling PRP under the current licensing arrangement with VETSTEM. We have since entered negotiations for a transition agreement with Vestem, which is currently underway. Meanwhile, we anticipate higher gross margin going forward with our sales force and distributors now focused on generating greater sales this spring with higher gross margins exceeding 90%. Total operating expenses in fiscal 2026 increased 8% to $9.8 million. The increase was primarily due to a loss and impairment for the precise PRP product line. Specifically, the increase in operating expense was primarily due to a 16% increase in sales and marketing expense to $3.1 million, with this related to commercialization of the Precise PRP product line. This increase was offset by a 10% reduction of general administrative costs and an 11% reduction in research and development expense. We also took a $1 million impairment expense for the Precise PRP product due to the lower than expected market acceptance. Also, due to the increased sales and marketing expense and the $1 million impairment expense, our operating loss increased 8.5% to $9.1 million. This increase contributed to a net loss for the fiscal year end of 2026 totaling $10.5 million or $0.38 per share as compared to a net loss of $8.4 million or $0.41 per share in the prior year. The net loss was also due to the increase in other expenses that included unrealized loss on change in derivative liabilities, loss on disposal of assets, amortization of debt discount, and interest expense under convertible notes. Net cash used in operating activities during the year totaled $6.1 million as compared to $5.3 million in fiscal ending 2025. John Lai, Bryan Monninger, Garry Lowenthal Now let's turn to our balance sheet. Our current assets totaled $1.8 million at March 31, 2026. In contrast, our current liabilities were substantially reduced to $1.4 million from $4.3 million at the end of the prior year, a decrease of 68%. We also had an 80% decrease in total liabilities from $5.1 million in the previous fiscal year to only $1.4 million in the year ending March 31, 2026. This significant improvement was due to the conversion of $1.6 million of convertible debt, a $798,000 reduction in our long-term lease obligations due to a lease termination, a $274,000 reduction of our accounts payables, Thank you for watching. The strongest balance sheet we've had in many, many years. In the final quarter of fiscal 2026, we raised additional capital from the exercise of warrants and the sale of equity securities, bringing in net proceeds of $877,500. This brought our working capital to $482,600 as of March 31st, 2026. Now this completes our financial review for the year. John?

Thank you, Garry. Throughout fiscal 2026, SPRING continued to receive favorable reports from veterinarians, especially regarding its ease of use and effectiveness in the management of osteoarthritis in horses and companion animals. Our diligent efforts also resulted in Health Canada, the federal agency responsible for regulating health products and protecting public health, officially recognizing Pet Vivo's SPRING with osteo-cushion technology as a veterinary medical device, which has initiated our efforts for commercialization in Canada. This important regulatory milestone expands our international commercial opportunities and reflects the quality and safety of our innovative technology. We believe this regulatory acknowledgement will lead to making spring with Osseocushion technology available in Canada as a veterinary and administered intra-articular injectable veterinary medical device intended to support joint health and aid in the management of lameness and other joint-related afflictions in animals. As what we believe is the first such recognition by an international regulatory body of a veterinary hydrogel medical device, this action represents a major milestone in our global commercialization strategy. It has also effectively created a new large international market opportunity for us and is and has paved the way for the commercial rollout of the spring in Canada which we are preparing to launch near the end of July. Preparation has included developing the proper product labeling for Canada including a version translated into French for certain Canadian customers. We've also been developing a distributor network in Canada like we have in the United States which we believe will speed our market expansion with little investment. We see the opportunity for Canada as quite substantial. The Canadian overall animal health care market is reportedly growing at a 6.8% CAGR and is expected to exceed $4.4 billion by 2031. Moreover, we believe we have meaningful first mover advantage in this significant market. To our knowledge, we believe our spring with Osseochristian technology is one of the first hydrogel-based intraarticular injectable veterinary medical devices to receive regulatory recognition from Health Canada that permits commercialization in Canada. We also continue to hear from veterinarians and distributors that there is substantial pent up demand for an innovative product that has been recognized by Health Canada for commercialization in the Canadian market. We believe we also have a competitive advantage with our clinical studies, particularly our canine studies. We believe our clinical data demonstrates the advantages of our spring technology over competitive products, including a better long-term safety profile. Also during the year, we continue to advance our strategic collaboration with Commonwealth Markets, the syndicated ownership group behind the 2023 Kentucky Derby winner. Commonwealth has integrated SPRING into the care protocols of its top tier thoroughbred stables where it is being used to promote joint health, extend performance longevity, and support recovery in high impact training and racing environments. This adoption by Commonwealth represents a strong validation of the effectiveness of SPRING and we believe will open doors to other significant opportunities. We have continued to expand the awareness of the benefits of SPRING among other key decision makers, including presenting at a number of major conferences earlier this year. This included the Florida Veterinary Medical Association Ocala Equine Conference, which was held at the World Equestrian Center in Ocala, Florida, the American College of Veterinary Sports Medicine and Rehabilitation Symposium in Lexington, Kentucky, and at the International Veterinary Academy of Pain Management Forum which was held in Dallas, Texas. At these events, we demonstrated the research-backed benefits of spring to veterinarians including leading surgeons, sports medicine, and rehabilitation experts in the veterinary industry. Such introductions are typically significant drivers of product adoption and new sales. We are planning to exhibit at several more conferences later this year which we plan to announce on our website in the coming months. The conferences also present the opportunity to share the results of recent studies, like our new canine elbow study, as well as other completed and published studies. We currently have additional canine equine studies for tolerance and efficacy of spring in the initial stages of development. We also continue to advance our pipeline of new products, with this greatly expanded and strengthened with the acquisition of PBM last week. This includes new functional biomaterials as well as tissue and bone mimicking biomaterials that may be used to enhance the delivery of pharmacological agents and or promote the regeneration, restoration, and or remodeling of damaged or injured tissue and bone in animals and humans. Our collagen elastin hydrogel particles or CEHM when combined with PBM technology can effectively create the structure or scaffolding and assist in facilitating biological activity for the body to restore and or remodel its natural tissue. The PDM technology enhanced CEHM integrates with the host tissue and assist in the remodeling and restoring of tissue to a more normal and healthy state. This includes animal and human applications such as using our functional biomaterial particle technology for physical and drug therapy treatments via the respiratory system using nebulizer. We are also investigating potential topical treatments for eye afflictions such as ocular ulcers as well as wound treatment where our functional biomaterial technology can help remodel and restore tissue to its original state. This could include assisting the healing process by delivering existing FDA-approved antibiotic, antiviral, and anesthetic substances. Beyond industry events, in May, we were also invited to present at the Market Movers Investor Summit, which was held at the Historic Bank of New York. The conference provided us an opportunity to elevate awareness of the company in the institutional investor community. The exclusive event featured a fireside chat by Alex Rodriguez, who many of you know to be one of the greater MLB players of all time. He is now the founder and chairman and CEO of the alternative investment group A-Rod Corp. It was a fun and exciting event for sure. Now another exciting event, which I had mentioned earlier, which occurred in the final quarter of the fiscal year, was Digitalandia's launch of its public access beta to its B2C agentic pet solution for pet owners. The B2C platform is designed to educate and engage pet owners while serving as a gateway to the company's planned B2B veterinary platform, creating an integrated ecosystem that facilitates collaboration between pet owners and veterinary professionals. The B2B launch will include access to all of its specialized AI agents, such as veterinarian, behavioral scientists, nutritionists, geneticists, vaccination specialists, trainers, radiologists, blood and fecal analysis, and Urinalysis Agents. Key for us is that its special B2B AI agents support the broader adoption of our veterinary products and services. The agents assist veterinarians in proactively diagnosing afflictions and diseases such as osteoarthritis and lameness and suggest treatment options. Agetic Pet's AI-powered diagnosis boasts an amazing 97% accuracy and has such robust represents a paradigm shift in the medical treatment of companion animals. The solution targets Gen Zers, who represent 20% of U.S. pet households with ownership growing more than 43% annually. Digital Landia reported that the public B2C beta launch of Agenic Pet crushed expectations with the onboarding of 1,000-plus active beta users in less than 72 hours. They believe this demonstrated pent-up demand for AI-driven preventive pet healthcare and confirmed that pet owners are seeking proactive solutions that catch health issues before symptoms emerge rather than relying on outdated reactive care models. The successful beta program is anticipated to strengthen the value proposition of our pet vivo AI B2B SaaS-based service offered for thousands of vet clinics in our nationwide network. Finally and recently, PetVivo AI achieved several important technology milestones that strengthened the foundation for future growth. This platform technology has deployed a highly resilient AI infrastructure, developed a proprietary AI platform with Persistent Patient Memory, and introduced smartphone-based diagnostic capabilities that have the potential to significantly expand access to veterinary care. The Agenic platform has also launched a data monetization framework, creating the opportunity for veterinary professionals to participate in the value generated from anonymized health data while integrating seamlessly into their existing practice management systems. As the regulatory landscape for digital health data continues to evolve, we believe PetVivo AI is well positioned to become an important data infrastructure platform serving veterinarians, pharmaceutical companies, and research organizations. And we are now focused on scaling the platform and expanding adoption. Altogether, our technologies have created an exciting future for PetVivo that is transformative to not only veterinarians and the patients they serve, but potentially for humans as well. Looking ahead, we expect to see continued sales momentum and market penetration for the duration of fiscal 2027 and beyond. In fact, we have never been in a better position to accelerate our growth and expand across high-growth U.S. and international markets. Industry analysis say that the U.S. animal market alone will double to $11.3 billion by 2030. Such massive growth is rare for such an already large industry and it therefore provides an exceptional strong tailwind. As we continue to grow and expand over the coming quarters, we will remain committed to advancing the best in pet health solutions and ensuring our products reach more veterinary professionals and pet owners, with our success in the efforts driving greater value for our stakeholders. Now I would like to turn the call over to our CEO, John Lai, to provide some additional insights into these recent developments and answer any questions from our listeners. John?

Thank you, John. One of the first things I'd like to bring up is our new Tier 1 program. AIR Marketing Program. We've put it in place close to 90 days and we have well over 30,000 people or emails that have agreed to get updates as we do some updates to the shareholders. So we are building a large base of interested people on what's happening with Pet Vivo, the company, and It's a really neat system where our customer acquisition costs or potential shareholder acquisition costs is extremely low. You know, John Dolan's done a very good job of talking about the digital land, the pet vivo AI, and the other components we have coming in. So we're looking, you know, one of the key catalysts we should be looking at as we move forward to year end. is our animal studies that we're doing with Paolo Biezo and the University of Connecticut. We anticipate these large animal studies to be completed right around calendar year end for dogs and horses. That will give us some very powerful marketing data to go into the veterinary market as we position the IDE filings into the human market for our spring and the nanofiber technology. You know, I'd just like to basically open it up now to Q&A. Operator, could you provide the instructions to our calling people for us to answer questions?

Hi, John. Yes, so everyone that joined over the phone, please dial star 9 to raise your hand. Or if you joined over the computer, please go to the toolbox select the react button and click raise your hand repeating instructions for anyone that going over the phone please dial star 9 to raise your hand or If you join over your computer, please go to the toolbox and react with raised hand.

Well, if we don't have any questions, I'll just give a quick little summary. We anticipate development of additional products, so just keep on our website. or get on to the AIIR program where we'll update you as we provide timetables of additional products coming in for both the human side as well as the animal side and we anticipate over the next 12 months there will be a lot of news announcements as well as continue updates. So if there's no more questions I will turn it over to John Dolan to provide wrap up and thank you everyone for joining us on the call.

Now before we conclude today's call, I would like to provide the company's safe harbor statement that includes cautions regarding forward-looking statements made during today's call. The information that we have provided in this conference call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. including but not limited to statements regarding the company's future revenue, future plans, objectives, expectations and events, assumptions and estimates. Forward-looking statements can be identified by the use of words or phrases usually containing the word believe, estimate, project, intend, expect, should, will or similar expressions. Statements that are not historical facts are based on the company's current expectations, beliefs, assumptions, estimates, forecasts and projections for its business and the industry and markets related to its business. Any forward-looking statements made during this conference call are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict. Actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, various risks as detailed in the company's periodic report filings with the U.S. Securities and Exchange Commission. For more information about risk and uncertainties associated with the company's business, please refer to the management's discussion and analysis of financial conditions or results of operations and risk factors section of the company's SEC filings, including but not limited to our annual report on the Form 10-K and quarterly reports on the Form 10-Q. Any forward-looking statements made during the conference call speaks as of today's date. The company expressly disclaims any obligations or undertakings to up Thank you for joining us. Please refer to today's earnings release for dial-in replay instructions available via the company's website at www.petvivo.com. Thank you for attending today's presentation. This concludes the conference call.